Document is current
Any future updates will be listed below
-
Authors
Shahswar, Rabia
Gabdoulline, Razif
Krueger, Katja
Wichmann, Martin
Götze, Katharina S.
Braitsch, Krischan
Meggendorfer, Manja https://orcid.org/0000-0002-9038-3265
Schmalbrock, Laura https://orcid.org/0000-0002-6080-6175
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
Modemann, Franziska https://orcid.org/0000-0002-5897-3310
Fiedler, Walter
Krauter, Juergen
Kaun, Stephan
Rotermund, Susanne
Voß, Andreas https://orcid.org/0000-0001-9647-5024
Behrens, Yvonne Lisa
Bergmann, Anke Katharina https://orcid.org/0000-0002-1367-2725
Koller, Elisabeth
Beutel, Gernot https://orcid.org/0000-0001-6758-6104
Thol, Felicitas https://orcid.org/0000-0001-5848-6152
Heidel, Florian https://orcid.org/0000-0003-2438-1955
Heuser, Michael https://orcid.org/0000-0001-5318-9044
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (HE 5240/6-2)
Deutsche Forschungsgemeinschaft (3696/3)
Deutsche Forschungsgemeinschaft (BE6555/1-1)
Deutsche Forschungsgemeinschaft (BE6555/2-1)
Deutsche Krebshilfe (70114189)
Deutsche Krebshilfe (70115044)
- License Information
-
More Information
Article History
Received: 14 May 2024
Revised: 22 November 2024
Accepted: 6 December 2024
First Online: 8 January 2025
Competing interests
: MH declares honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda, paid consultancy for Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo, and research funding to his institution from Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche. RS declares support for meeting attendance from AbbVie. EK declares honoraria and/or travel support from Abbvie, JAZZ, BMS, Otsuka, Servier. WF declares honoraria from Jazz Pharmaceuticals, Pfizer, Amgen, Abbvie, Celgene, MorphoSys, Ariad/Incyte, Stemline Therapeutics, Clinigen, Daiichi Sankyo, Otsuka and Servier outside the submitted work; in addition, research support from Apis; patent issued with Amgen; support for medical writing for Amgen, Pfizer, and AbbVie. KSG declares honoraria from BMS and Abbvie. FM declares support for meeting attendance from Servier, AbbVie, Incyte, Gilead, Jazz Pharmaceuticals, Novartis, Teva, Pfizer, and Amgen, support for medical writing from Servier, and Springer Verlag, research support from Apis Technologies, and Daiichi Sankyo, honoraria from Servier, Jazz Pharmaceuticals, and AbbVie. The other authors declare no conflict of interest.
: The registry was approved by the local Ethics Review Committee (ethical vote No.7972_BO_K_2018).
: All patients had given written informed consent to the off-label use of venetoclax, genetic analysis and use of clinical data according to the Declaration of Helsinki and institutional guidelines.
